Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Carcinoma, Hepatocellular 2 Pancreatic Neoplasms 1 Neoplasms, Glandular and Epithelial 1 Neoplasms by Site 1 Neoplasms by Histologic Type 1 Neoplasms 1 Melanoma 1 Locally Advanced Rectal Adenocarcinoma 1 Locally Advanced Cervical Carcinoma 1 Liver Neoplasms 1 Liver Diseases 1 Head and Neck Neoplasms 1 Gastric Cancer With Liver Metastases 1 Esophageal Neoplasms 1 Digestive System Neoplasms 1 Digestive System Diseases 1 Colorectal Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma 1 Breast Neoplasms 1 Adenocarcinoma 1

Interventions

pembrolizumab 9 Cetuximab 5 Surveys and Questionnaires 4 Cisplatin 4 dostarlimab 2 abemaciclib 2 Standard of Care 2 Docetaxel 2 Carboplatin 2 130-nm albumin-bound paclitaxel 2 ulixertinib 1 trastuzumab deruxtecan 1 toripalimab 1 tislelizumab 1 tipifarnib 1 ribociclib 1 repotrectinib 1 patritumab deruxtecan 1 palbociclib 1 olaparib 1 nimotuzumab 1 monalizumab 1 ibrutinib 1 fludarabine 1 exemestane 1 entrectinib 1 ebselen 1 durvalumab 1 disitamab vedotin 1 avelumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Head and Neck Neoplasms × Immunotherapy × 30 days × Clear all

NCT05328024 2026-06-05

IPRICE

Centre Paul Strauss

Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡